Cargando…
Autoinflammatory manifestations in adult patients
Autoinflammatory diseases represent a family of immune-mediated conditions characterized by the unchecked activation of innate immunity. These conditions share common clinical features such as recurrent fever, inflammatory arthritis, and elevation of acute phase reactants, in the absence of an ident...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985169/ https://www.ncbi.nlm.nih.gov/pubmed/36334040 http://dx.doi.org/10.1093/cei/uxac098 |
_version_ | 1784900895659524096 |
---|---|
author | Rodolfi, Stefano Nasone, Irene Folci, Marco Selmi, Carlo Brunetta, Enrico |
author_facet | Rodolfi, Stefano Nasone, Irene Folci, Marco Selmi, Carlo Brunetta, Enrico |
author_sort | Rodolfi, Stefano |
collection | PubMed |
description | Autoinflammatory diseases represent a family of immune-mediated conditions characterized by the unchecked activation of innate immunity. These conditions share common clinical features such as recurrent fever, inflammatory arthritis, and elevation of acute phase reactants, in the absence of an identified infectious etiology, generally without detectable serum autoantibodies, with variable response to glucocorticoids and in some cases colchicine, which represented the mainstay of treatment until cytokine blockade therapies became available. The first autoinflammatory diseases to be described were monogenic disorders caused by missense mutations in inflammasome components and were recognized predominantly during childhood or early adulthood. However, the progress of genetic analyses and a more detailed immunological phenotyping capacity led to the discovery a wide spectrum of diseases, often becoming manifest or being diagnosed in the adult population. The beneficial role of targeting hyperinflammation via interleukin 1 in complex non-immune-mediated diseases is a field of growing clinical interest. We provide an overview of the autoinflammatory diseases of interest to physicians treating adult patients and to analyze the contribution of hyperinflammation in non-immune-mediated diseases; the result is intended to provide a roadmap to orient scientists and clinicians in this broad area. |
format | Online Article Text |
id | pubmed-9985169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-99851692023-03-05 Autoinflammatory manifestations in adult patients Rodolfi, Stefano Nasone, Irene Folci, Marco Selmi, Carlo Brunetta, Enrico Clin Exp Immunol Review Autoinflammatory diseases represent a family of immune-mediated conditions characterized by the unchecked activation of innate immunity. These conditions share common clinical features such as recurrent fever, inflammatory arthritis, and elevation of acute phase reactants, in the absence of an identified infectious etiology, generally without detectable serum autoantibodies, with variable response to glucocorticoids and in some cases colchicine, which represented the mainstay of treatment until cytokine blockade therapies became available. The first autoinflammatory diseases to be described were monogenic disorders caused by missense mutations in inflammasome components and were recognized predominantly during childhood or early adulthood. However, the progress of genetic analyses and a more detailed immunological phenotyping capacity led to the discovery a wide spectrum of diseases, often becoming manifest or being diagnosed in the adult population. The beneficial role of targeting hyperinflammation via interleukin 1 in complex non-immune-mediated diseases is a field of growing clinical interest. We provide an overview of the autoinflammatory diseases of interest to physicians treating adult patients and to analyze the contribution of hyperinflammation in non-immune-mediated diseases; the result is intended to provide a roadmap to orient scientists and clinicians in this broad area. Oxford University Press 2022-11-05 /pmc/articles/PMC9985169/ /pubmed/36334040 http://dx.doi.org/10.1093/cei/uxac098 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Rodolfi, Stefano Nasone, Irene Folci, Marco Selmi, Carlo Brunetta, Enrico Autoinflammatory manifestations in adult patients |
title | Autoinflammatory manifestations in adult patients |
title_full | Autoinflammatory manifestations in adult patients |
title_fullStr | Autoinflammatory manifestations in adult patients |
title_full_unstemmed | Autoinflammatory manifestations in adult patients |
title_short | Autoinflammatory manifestations in adult patients |
title_sort | autoinflammatory manifestations in adult patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985169/ https://www.ncbi.nlm.nih.gov/pubmed/36334040 http://dx.doi.org/10.1093/cei/uxac098 |
work_keys_str_mv | AT rodolfistefano autoinflammatorymanifestationsinadultpatients AT nasoneirene autoinflammatorymanifestationsinadultpatients AT folcimarco autoinflammatorymanifestationsinadultpatients AT selmicarlo autoinflammatorymanifestationsinadultpatients AT brunettaenrico autoinflammatorymanifestationsinadultpatients |